Department of Infectious Diseases, Bern University Hospital, Bern, Switzerland.
Department of Infectious Diseases, Bern University Hospital, Bern, Switzerland.
J Hosp Infect. 2015 Nov;91(3):250-6. doi: 10.1016/j.jhin.2015.08.015. Epub 2015 Aug 29.
Chronic haemodialysis patients are a high-risk population for meticillin-resistant Staphylococcus aureus (MRSA) colonization, which is a precursor of infection.
To summarize the effect of nasal (± whole-body wash) MRSA decolonization in haemodialysis patients by means of a systematic review and meta-analysis.
We identified eligible studies using Medline, Embase, the Cochrane database, clinicaltrials.org, and conference abstracts investigating the success of MRSA decolonization in haemodialysis patients. For the statistical analysis, we used Stata 13 to express study-specific proportions with 95% confidence intervals. A likelihood ratio test was used to assess inter-study heterogeneity.
Six published prospective cohort studies and one study described in a conference abstract met our inclusion criteria. From 1150 haemodialysis patients enrolled in these studies, MRSA was isolated from nasal swabs of 147 (12.8%) patients. Six of the trials used mupirocin nasal ointment and combined it with chlorhexidine body washes for decolonization. The most widely used protocol was a five-day course of mupirocin nasal ointment application three times a day, and chlorhexidine body wash once daily. The pooled success rate of decolonization was 0.88 (95% confidence interval: 0.75-0.95). A likelihood ratio test of the fixed versus the random-effects model showed significant inter-study heterogeneity (P = 0.047). Four of seven studies determined subsequent MRSA infections in 94 carriers overall, two (2%) of which experienced infection.
The use of mupirocin together with whole-body decolonization is highly effective in eradicating MRSA carriage in haemodialysis patients. The current literature, however, is characterized by a lack of comparative effectiveness studies for this intervention.
慢性血液透析患者是耐甲氧西林金黄色葡萄球菌(MRSA)定植的高危人群,而定植是感染的前兆。
通过系统评价和荟萃分析总结血液透析患者鼻腔(+全身清洗)MRSA 去定植的效果。
我们使用 Medline、Embase、Cochrane 数据库、clinicaltrials.org 和会议摘要,检索了关于血液透析患者 MRSA 去定植成功的研究,以确定合格的研究。对于统计分析,我们使用 Stata 13 表达研究特异性比例及其 95%置信区间。使用似然比检验评估研究间异质性。
从纳入的 1150 名血液透析患者中,有 147 名(12.8%)患者的鼻腔拭子中分离出了 MRSA。六项试验使用莫匹罗星鼻软膏,并结合洗必泰全身清洗进行去定植。最广泛使用的方案是为期五天的莫匹罗星鼻软膏,每天三次,每日一次洗必泰全身清洗。去定植的总成功率为 0.88(95%置信区间:0.75-0.95)。固定效应模型与随机效应模型的似然比检验显示存在显著的研究间异质性(P=0.047)。在 94 名携带患者中,有 4 项研究确定了总的后续 MRSA 感染,其中 2 人(2%)发生了感染。
莫匹罗星联合全身去定植对清除血液透析患者中的 MRSA 定植非常有效。然而,目前的文献缺乏这种干预措施的比较有效性研究。